Search Results
Your search for The ,The matches 34679 pages
Showing 34101 - 34150Higher Post-Treatment FDG-PET Standardized Uptake Value Associated With Poorer Survival in Locally Advanced NSCLC
In a trial (ACRIN 6668/RTOG 0235 trial) reported in Journal of Clinical Oncology, Mitchell Machtay, MD, of Case Western Reserve University, and colleagues assessed the relationship between standardized uptake value for 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and survival in...
Increases in Melanoma Incidence and Mortality Unremitting Over 6 Decades, Study Finds
In a study reported in Journal of Clinical Oncology, Alan C. Geller, MPH, RN, of the Harvard School of Public Health, and colleagues assessed long-term trends in the incidence and mortality of melanoma in Connecticut, a state with complete and consistent tumor registration. They found...
For Pregnant Women With Lymphoma, Standard Combination Chemotherapy Given After First Trimester Associated With Few Complications
Lymphoma is the fourth most frequent cancer to occur during pregnancy. In a multicenter retrospective analysis reported in Journal of Clinical Oncology, Andrew M. Evens, DO, MSc, of Tufts University Medical School, and colleagues examined treatment, complications, and outcomes for Hodgkin lymphoma...
ASTRO: Intensity Modulated Proton Therapy May Preserve Quality of Life in Patients With Oropharyngeal Cancer
A new study from researchers at The University of Texas MD Anderson Proton Therapy Center found that the use of feeding tubes in patients with oropharyngeal cancer treated with intensity modulated proton therapy decreased by more than 50% compared to patients treated with intensity modulated...
Large Retrospective Study Finds Association Between Marriage and Cancer Outcomes
New results from a large retrospective study of the National Cancer Institute’s SEER database, published in the Journal of Clinical Oncology, show that patients with cancer who were married at the time of diagnosis live markedly longer compared to unmarried patients. Researchers also found...
Abiraterone Acetate/Prednisone Combination Delays Decline in Quality of Life in Men With Metastatic Prostate Cancer
According to a study published in The Lancet Oncology, abiraterone acetate (Zytiga) taken in conjunction with prednisone significantly delays progression of pain and quality of life deterioration in men with metastatic castration-resistant prostate cancer. The study was led by Ethan Basch, MD,...
Phase II Study Shows Activity of Selective Aurora A Kinase Inhibitor Alisertib in Relapsed/Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphoma
Aurora A kinase is overexpressed in aggressive lymphomas and may correlate with more histologically aggressive forms of disease. In a phase II study reported in Journal of Clinical Oncology, Jonathan W. Friedberg, MD, of University of Rochester Wilmot Cancer Center, and colleagues assessed the...
Colonoscopy Associated With Reduction in Overall, Distal, and Proximal Colorectal Cancer Incidence and Mortality
Colonoscopy and sigmoidoscopy have been shown to provide protection against colorectal cancer, but the magnitude and duration of protection, particularly against proximal colon cancer, remain undefined. A study of long-term colorectal cancer incidence and mortality after lower endoscopy reported in ...
Sunscreen Use Infrequently Discussed With Patients, Even Those With History of Skin Cancer
Although the incidence of skin cancer is increasing, “the rate at which physicians are mentioning sunscreen at patient visits is quite low, even for patients with a history of skin cancer,” according to an analysis of data from more than 18.30 billion patient visits....
Myeloma Foundation Launches Open Access Gateways to Accelerate Drug Development
The Multiple Myeloma Research Foundation (MMRF) has announced two open access gateways, the MMRF Researcher Gateway, which will upload genomic data as it becomes available and make it accessible to all researchers, and the MMRF CoMMunity Gateway, which will aggregate subtypes of myeloma patients...
ASTRO: Younger Adults With a Limited Number of Brain Metastases Have Improved Overall Survival After Stereotactic Radiosurgery Alone
When treated with stereotactic radiosurgery that is not combined with whole-brain radiotherapy, adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented on Sunday, September 22, at the American Society for Radiation...
ASTRO: Proton Therapy Yields Encouraging Outcomes for Pediatric Brain Tumor Patients
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented on Sunday, September 22, at the American Society for Radiation Oncology’s 55th Annual Meeting...
USPSTF Issues Final Recommendation Statement on Medications for the Risk Reduction of Primary Breast Cancer in Women
The U.S. Preventive Services Task Force (USPSTF) released today its final recommendation statement on medications to reduce the risk of primary breast cancer in women. Clinicians are recommended to prescribe risk-reducing medications, such as tamoxifen or raloxifene, for women who are at increased...
HERA Trial Shows No Benefit of 2 Years vs 1 Year of Trastuzumab, Significant Survival Benefits of 1 Year vs Observation in Early Breast Cancer
As reported in The Lancet by Aron Goldhirsch, MD, of the European Institute of Oncology in Milan, and colleagues, 2 years of trastuzumab (Herceptin) showed no advantage over 1 year of trastuzumab treatment in patients with HER2-positive early breast cancer in the phase III HERA trial. An update of...
ASTRO: Cisplatin Plus Radiation Therapy for Advanced Cervical Cancer Improves Disease-Free Survival vs Radiotherapy Alone
Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy and high–dose rate brachytherapy for stage IIIB cervical cancer is beneficial, according to research presented on September 22, 2013, at the American Society for Radiation Oncology’s 55th Annual Meeting...
ASTRO: Fewer Weeks of Neoadjuvant Hormone Therapy Reduces Side Effects in Patients With Intermediate-Risk Prostate Cancer
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to an extended course of androgen suppression therapy, yields comparable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the...
ASTRO: Long-Term Androgen Deprivation in Patients With Intermediate-Risk Prostate Cancer Does Not Improve Overall Survival
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy. Investigators concluded that there were no additional benefits when compared to short-term...
Childhood Cancer Survivors Who Received Nephrotoxic Therapy May Be at Greater Risk for Late Renal Problems
A large study assessing glomerular function in adult survivors of childhood cancers who were treated with certain chemotherapy drugs or kidney surgery found that they had worse kidney function, which did not recover over time, compared with adult survivors who were not given nephrotoxic therapy....
Antiviral Treatment Improves Recurrence-Free and Overall Survival in HBV-Related Hepatocellular Carcinoma
Patients with hepatitis B virus (HBV)-related hepatocellular carcinoma have poor postoperative prognosis. In a study reported in Journal of Clinical Oncology, Jianhua Yin, MD, of the Second Military Medical University in Shanghai, and colleagues assessed the effects of nucleotide/nucleoside analog...
NCCN: Practical Considerations in Selecting Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
Although imatinib (Gleevec) is the initial therapy for chronic myeloid leukemia (CML), several second-generation tyrosine kinase inhibitors are now approved for the treatment of this disease. Michael Millenson, MD, of Fox Chase Cancer Center in Philadelphia, reviewed practical considerations in...
NCCN: PET-Guided Therapy for Hodgkin Lymphoma Moving Into Clinical Practice
Interim positron emission tomography (PET) scan is being used to guide risk-adapted therapy in patients with early-stage and advanced-stage Hodgkin lymphoma for clinical research at academic centers, and experts predict that this will become standard of care in clinical practice. At the NCCN 8th...
Mindfulness-Based Stress Reduction Superior to Supportive-Expressive Therapy for Distressed Survivors of Breast Cancer
Mindfulness-based cancer recovery was shown in to be superior to supportive-expressive group therapy decreasing symptoms of stress and improving overall quality of life and social support among survivors of stage I to III breast cancer who were distressed, according to a study reported in Journal...
Pomalidomide Produces ‘Impressive Results’ in Patients With Multiple Myeloma Who Are Refractory to Bortezomib and Lenalidomide
The second-generation immunomodulatory drug pomalidomide (Pomalyst) “has shown impressive results in patients with multiple myeloma who are refractory to lenalidomide and bortezomib,” according to a review of clinical data leading to the drug’s approval by the U.S. Food and Drug...
Researchers Uncover Root Cause of Multiple Myeloma Relapse
Researchers have discovered why multiple myeloma frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. The study, published in Cancer Cell, was a collaboration between researchers at Princess Margaret Hospital in Toronto, Mayo Clinic in...
Scientists Find Possible Antidote for Tamoxifen-Induced Mental Fog
Researchers from University of Rochester Medical Center have shown scientifically what many women report anecdotally: that tamoxifen is toxic to cells of the brain and central nervous system (CNS), producing mental fogginess similar to “chemo brain.” In the study, published in the...
Deficient DNA Mismatch Repair Associated With Favorable Prognosis in Proximal Tumors in Stage III Colon Cancer Patients Receiving Adjuvant FOLFOX
In an analysis reported in Journal of Clinical Oncology, Frank A. Sinicrope, MD, of the Mayo Clinic and North Central Cancer Treatment Group (NCCTG), and colleagues investigated the association of deficient DNA mismatch repair with prognosis in patients with stage III colon cancer treated with...
Reduced Long-Term Survival and Increased Risk of Secondary Cancer in Younger Women After External Pelvic Radiation for Early-Stage Endometrial Cancer
In a study reported in Journal of Clinical Oncology, Mathias Onrud, MD, of Norwegian Radium Hospital, Oslo University Hospital, and colleagues assessed outcomes in the follow-up of the Norwegian Radium Hospital trial to determine long-term effects of external beam radiation therapy in the adjuvant...
Japanese Study Shows Endoscopic Dual Tracer Method for Sentinel Node Mapping in Gastric Cancer Is Safe and Accurate
In a study reported in Journal of Clinical Oncology, Yuko Kitagawa, MD, FACS, of Keio University School of Medicine, and colleagues found that sentinel node mapping using a standardized dual tracer endoscopic injection technique was safe and accurate in patients with gastric cancer. Study Details ...
Widespread Contraindicated Use of Bevacizumab in Elderly Patients
In a study reported in Journal of Clinical Oncology, Dawn L. Hershman, MD, MS, of Columbia University, and colleagues assessed the use of bevacizumab in older patients with metastatic breast, lung, or colon cancer. They found that bevacizumab (Avastin) was contraindicated in approximately one-third ...
Meta-Analysis Suggests Fluorouracil or Gemcitabine Is Optimum Adjuvant Treatment for Pancreatic Cancer
A meta-analysis reported in The Lancet Oncologyby Wei-Chih Liao, MD, of National Taiwan University Hospital and colleagues indicates that fluorouracil (5-FU) or gemcitabine is optimal adjuvant therapy for pancreatic adenocarcinoma. Chemoradiation was associated with poorer survival and...
Presence of RAS Mutations in Metastatic Colorectal Cancer Predictive of Negative Response to Panitumumab/FOLFOX4 Treatment
Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-EGFR therapy. However, other activating RAS mutations may predict poorer outcome with anti-EGFR therapy. In an analysis reported in The New England Journal of Medicine by Jean-Yves Douillard,...
Statement by ASCO President Clifford A. Hudis, MD, FACP, in Support of the Rally for Medical Research Hill Day
“With the unprecedented scientific opportunities now promising significant progress against cancer and other life-threatening diseases, it is a tragedy that we are even considering cuts to our nation's investment in biomedical research. Yet, such cuts are already happening because of the...
MicroRNA Molecule Found to Be a Potent Tumor Suppressor in Lung Cancer
New research shows that microRNA-486 (miR-486) is a potent tumor-suppressor molecule in lung cancer, and that it helps regulate the proliferation and migration of lung cancer cells, as well as the induction of apoptosis in those cells. Published in the Proceedings of the National Academy of...
Young Breast Cancer Patients May Overestimate Benefit of Contralateral Prophylactic Mastectomy
Young women with breast cancer may overestimate the risk that cancer will occur in their other healthy breast and decide to undergo contralateral prophylactic mastectomy, a survey conducted by Dana-Farber Cancer Institute investigators indicated. The survey also shows that many patients may opt for ...
PDK1 Gene Identified as New Target for Melanoma Treatment
According to new research at Sanford-Burnham Medical Research Institute a gene encoding the enzyme phosphoinositide-dependent kinase-1 (PDK1) plays an essential role in the development and progression of melanoma. The finding, published online in Oncogene, may offer insight toward a new approach to ...
Addition of Bevacizumab to Capecitabine Improves Progression-Free Survival in Elderly Patients with Previously Untreated Metastatic Colorectal Cancer
Elderly patients are often underrepresented in clinical trials of metastatic colorectal cancer. In a phase III study (AVEX trial) reported in The Lancet Oncology, David Cunningham, MD, of Royal Marsden Hospital in London and colleagues assessed the addition of bevacizumab (Avastin) to capecitabine...
Tremelimumab Shows Some Activity in Chemotherapy-Resistant Advanced Malignant Mesothelioma, Phase II Study Finds
Tremelimumab is an anticytotoxic T-lymphocyte antigen 4 (CTLA4) monoclonal antibody, a class of inhibitor that has shown activity in multiple tumor types. Ipilimumab (Yervoy), another agent in this class, was found to significantly prolong overall survival in metastatic melanoma despite a...
New Medical Device Treats Urinary Symptoms Related to Benign Prostatic Hyperplasia
The U.S. Food and Drug Administration has authorized the marketing of the UroLift system, a permanent implant to relieve low or blocked urine flow in men age 50 and older with benign prostatic hyperplasia. As men age, the prostate can become enlarged, also known as benign prostatic hyperplasia....
FDA Grants Priority Review Designation for Dabrafenib/Trametinib Combination in Metastatic Melanoma
GlaxoSmithKline recently announced that the U.S. Food and Drug Administration has granted Priority Review designation to its supplemental New Drug Applications for the combined use of dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of adult patients with unresectable or metastatic ...
FDA Grants Volasertib Breakthrough Therapy Designation in Acute Myeloid Leukemia
Boehringer Ingelheim Pharmaceuticals, Inc, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase (Plk), which being evaluated for the treatment of patients aged 65 or older with...
Exploratory Analysis Suggests Response-Guided Neoadjuvant Therapy for Breast Cancer May Improve Survival
In an exploratory analysis of long-term survival data from the GeparTrio trial reported in Journal of Clinical Oncology, Gunter von Minckwitz, MD, of the German Breast Group in Neu-Isenburg, and colleagues found that response-guided neoadjuvant chemotherapy appears to improve disease-free survival...
Phase II Study Shows Durable Effect of Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma
In a phase II study (MCL-001, EMERGE) reported in Journal of Clinical Oncology, Andre Goy, MD, of Hackensack University Medical Center, and colleagues evaluated the use of single-agent lenalidomide (Revlimid) in bortezomib (Velcade)-treated patients who had relapsed/refractory mantle cell lymphoma. ...
AACR Issues 2013 Cancer Progress Report
The American Association for Cancer Research (AACR) released its Cancer Progress Report 2013 today. And while there is much to celebrate in the significant progress made in cancer research—which has led to more effective therapies for the more than 200 types of cancer and increased...
FDA Approves First Generic Capecitabine to Treat Colorectal and Breast Cancers
The U.S. Food and Drug Administration (FDA) has approved the first generic version of capecitabine (Xeloda), an oral chemotherapy agent used in the treatment of metastatic colorectal cancer and breast cancers. Teva Pharmaceuticals USA has gained FDA approval to market generic capecitabine in 150...
New Plasma Biomarker Identified for the Diagnosis of Lung Cancer
A new plasma biomarker, isocitrate dehydrogenase 1 (IDH1), has been shown to be more sensitive in detecting non–small cell lung cancer (NSCLC) than currently used biomarkers, including CEA, Cyfra21-1, and CA125, according to a study published in Clinical Cancer Research. The study by Jie He,...
FDA Grants Ofatumumab Breakthrough Therapy Designation for Previously Untreated CLL
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ofatumumab (Arzerra) in combination with chlorambucil (Leukeran) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior treatment and are inappropriate for...
Gene Expression–Based Biomarker Predicts Long-Term Risk of Breast Cancer Recurrence
A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor–positive breast cancer found that only the breast cancer index (BCI)—a biomarker based on the expression levels of seven tumor-specific genes—accurately identified patients...
Test Could Identify Which Prostate Cancers Require Treatment
The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center (CUMC). Use of this three-gene...
Tivozanib Improves Progression-Free Survival but Not Overall Survival vs Sorafenib in Metastatic Renal Cell Carcinoma
Tivozanib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. In a phase III trial reported in Journal of Clinical Oncology by Robert J. Motzer, MD, of Memorial Sloan-Kettering Cancer Center (MSKCC) and colleagues, tivozanib was found to...
Models Estimate Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
In a study reported in The New England Journal of Medicine, Annette McWilliams, MD, of Vancouver General Hospital, and colleagues analyzed data from subjects undergoing low-dose computed tomography (CT) screening for lung cancer to identify factors that might predict whether lung nodules found on...
